Swiss National Bank
HZNP

Swiss National Bank’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Swiss National Bank’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-699,656
Closed -$80.9M – 2642
2023
Q3 		$80.9M Sell
699,656
-84,200
-11% -$9.05M 0.06% 283
2023
Q2 		$80.6M Sell
783,856
-70,500
-8% -$7.44M 0.05% 328
2023
Q1 		$93.2M Sell
854,356
-35,200
-4% -$3.89M 0.06% 301
2022
Q4 		$101M Sell
889,556
-56,912
-6% -$4.73M 0.07% 276
2022
Q3 		$58.6M Buy
946,468
+13,200
+1% +$922K 0.04% 395
2022
Q2 		$74.4M Hold
933,268
– – 0.05% 354
2022
Q1 		$98.2M Buy
933,268
+117,600
+14% +$11.5M 0.06% 322
2021
Q4 		$87.9M Sell
815,668
-28,900
-3% -$3.15M 0.05% 335
2021
Q3 		$92.5M Sell
844,568
-23,400
-3% -$2.43M 0.06% 312
2021
Q2 		$81.3M Buy
867,968
+19,212
+2% +$1.77M 0.05% 366
2021
Q1 		$78.1M Buy
848,756
+16,700
+2% +$1.41M 0.05% 358
2020
Q4 		$60.9M Buy
832,056
+416,600
+100% +$31M 0.04% 409
2020
Q3 		$32.3M Sell
415,456
-9,000
-2% -$619K 0.03% 519
2020
Q2 		$23.6M Buy
424,456
+61,200
+17% +$2.62M 0.02% 575
2020
Q1 		$10.8M Buy
363,256
+6,300
+2% +$213K 0.01% 657
2019
Q4 		$12.9M Buy
356,956
+9,100
+3% +$279K 0.01% 682
2019
Q3 		$9.47M Buy
347,856
+32,200
+10% +$833K 0.01% 776
2019
Q2 		$7.59M Buy
315,656
+10,200
+3% +$259K 0.01% 886
2019
Q1 		$8.07M Buy
305,456
+10,800
+4% +$256K 0.01% 833
2018
Q4 		$5.76M Buy
294,656
+6,800
+2% +$133K 0.01% 904
2018
Q3 		$5.64M Buy
287,856
+3,400
+1% +$64.6K 0.01% 1034
2018
Q2 		$4.71M Hold
284,456
– – 0.01% 1147
2018
Q1 		$4.04M Buy
284,456
+6,300
+2% +$93.1K ﹤0.01% 1178
2017
Q4 		$4.06M Buy
278,156
+7,800
+3% +$110K ﹤0.01% 1190
2017
Q3 		$3.43M Hold
270,356
– – ﹤0.01% 1271
2017
Q2 		$3.21M Buy
270,356
+31,300
+13% +$389K ﹤0.01% 1277
2017
Q1 		$3.53M Buy
239,056
+3,700
+2% +$59.9K ﹤0.01% 1204
2016
Q4 		$3.81M Hold
235,356
– – 0.01% 1137
2016
Q3 		$4.27M Sell
235,356
-8,200
-3% -$160K 0.01% 1007
2016
Q2 		$4.01M Buy
243,556
+21,500
+10% +$348K 0.01% 1042
2016
Q1 		$3.55M Buy
222,056
+44,000
+25% +$770K 0.01% 1075
2015
Q4 		$3.86M Buy
178,056
+4,400
+3% +$85.7K 0.01% 920
2015
Q3 		$3.44M Buy
173,656
+26,400
+18% +$834K 0.01% 978
2015
Q2 		$5.12M Buy
147,256
+60,956
+71% +$1.86M 0.01% 760
2015
Q1 		$2.24M Buy
86,300
+1,800
+2% +$33K 0.01% 1218
2014
Q4 		$1.09M Buy
84,500
+26,200
+45% +$328K ﹤0.01% 1678
2014
Q3 		$716K Buy
58,300
+10,900
+23% +$127K ﹤0.01% 1859
2014
Q2 		$750K Buy
+47,400
New +$677K ﹤0.01% 1899

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swiss National Bank's HZNP Position: Q4 2023 in Review

Swiss National Bank sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 699,656 shares — an estimated $80.9M sold.

Swiss National Bank first reported a position in HZNP in Q2 2014 and held it in 38 quarters. The position peaked at $101M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Swiss National Bank reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Swiss National Bank sold 699,656 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.9M.
  • Swiss National Bank first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 38 quarters.
  • Swiss National Bank's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $101M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.